/CVS
CVS Health Corporation
CVS • NYSECVS • NYSE • Healthcare
$77.92-0.98%-0.77
$77.92-0.98%(-0.77)Healthcare
GoAI Score
Sign in to unlock
Valuation
50Fair Value
Sentiment
92Bullish
Risk
100Low Risk
Momentum
57Neutral
Institutional-Grade Intelligence
🏆PRO
Actionable Intelligence
AI-driven stance, execution logic & risk thresholds
Catalyst Roadmap
Event timeline with expected impact & market context
Deep Insights
Fact-checked analysis & score logic breakdown
Financial Statements
Margin Trends
Gross
13.8%▼0.0pp
Revenue after COGS
Operating
2.6%▲0.3pp
After operating expenses
Net
0.4%▼0.8pp
Bottom-line profitability
Gross Margin
Operating Margin
Net Margin
Valuation Snapshot
P/E Ratio
56.9
Price vs earnings
EV/EBITDA
18.8
Enterprise value
FCF Yield
7.8%
Cash generation
Earnings Yield
1.8%
Inverse of P/E
Capital Efficiency
3
GoAI Quality ScoreWeak
ROEReturn on Equity
2.4%Fair
ROAReturn on Assets
0.7%Fair
ROICReturn on Invested Capital
4.7%Fair
Financial Health
Current RatioWeak
0.84
Short-term solvency (>1.5)
Net Debt / EBITDAHigh
8.63x
Debt repayment capacity (<3x)
Income QualityStrong
6.02
Cash backs earnings (>1)
Revenue & Profitability
Revenue
Net Income
Net Loss
Income Statement
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $402.07B | $372.81B | $357.78B | $322.47B | $292.11B |
| Gross Profit | $55.36B | $51.40B | $54.43B | $54.50B | $52.12B |
| Gross Margin | 13.8% | 13.8% | 15.2% | 16.9% | 17.8% |
| Operating Income | $10.38B | $8.52B | $13.74B | $7.95B | $13.31B |
| Net Income | $1.77B | $4.61B | $8.34B | $4.31B | $8.00B |
| Net Margin | 0.4% | 1.2% | 2.3% | 1.3% | 2.7% |
| EPS | $1.40 | $3.66 | $6.49 | $3.29 | $6.00 |
Average Price Target
$95.15▲ 22.1% Upside
Past 12 Months
12 Month Forecast
Based on 50 Wall Street analysts offering 12 month price targets for CVS Health Corporation, the average price target is $95.15, with a high forecast of $103.00 and a low forecast of $90.00. The average price target represents a 22.1% increase from the current price of $77.92.
Highest
$103.00
Average
$95.15
Lowest
$90.00
Rating Distribution
Strong Buy
2
5%
Buy
32
78%
Hold
7
17%
Sell
0
0%
Strong Sell
0
0%
Recent Analyst Ratings
FirmActionRatingDate
Argus Research● Maintain
Buy
2026-01-28B of A Securities● Maintain
Buy
2026-01-27JP Morgan● Maintain
Overweight
2025-12-17Bernstein● Maintain
Market Perform
2025-12-12Truist Securities● Maintain
Buy
2025-12-10UBS● Maintain
Buy
2025-12-10Morgan Stanley● Maintain
Overweight
2025-12-10Mizuho● Maintain
Outperform
2025-12-10Baird● Maintain
Outperform
2025-12-10Barclays● Maintain
Overweight
2025-12-10Earnings History & Surprises
BEAT RATE
89%
Last 18 quarters
AVG SURPRISE
+7.0%
EPS vs Estimate
BEATS / MISSES
16/2
Last 18 quarters
LATEST EPS
$1.09
Q1 '26
QUARTERLY EPS TREND
Estimated
Beat
Miss
QUARTERLY DETAIL
Q1 '26
+9.0%
$1.09 vs $1.00
Q4 '25
+16.8%
$1.60 vs $1.37
Q3 '25
+24.0%
$1.81 vs $1.46
Q2 '25
+32.4%
$2.25 vs $1.70
Q1 '25
+30.2%
$1.19 vs $0.91
Q4 '24
-24.3%
$1.09 vs $1.44
Q3 '24
+5.8%
$1.83 vs $1.73
Q2 '24
-22.9%
$1.31 vs $1.70
Q1 '24
+5.5%
$2.12 vs $2.01
Q4 '23
+3.8%
$2.21 vs $2.13
Q3 '23
+4.2%
$2.21 vs $2.12
Q2 '23
+6.3%
$2.20 vs $2.07
No investor questions available.
Latest News
No news available